OnCo
companiesCompany

Summit Therapeutics

Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.

HARMONi-3 (first-line NSCLC) and HARMONi-7 (PD-L1-high NSCLC) phase 3; BLA strategy following HARMONi OS result.

Headquarters
Miami, FL, US
Type
biotech · SMMT

Products

1top
Under reviewBispecific antibody (PD-1×VEGF)
Ivonescimab

A Chinese bispecific that beat Keytruda head-to-head on progression-free survival in lung cancer, the first drug ever to do so.

Key papers

1top
rctThe Lancet 2025
HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer

For the first time a new drug has beaten pembrolizumab, the global first-line standard, in a randomised lung cancer trial, and it did so by combining checkpoint blockade with anti-angiogenesis in one molecule. For patients outside China nothing changes yet: the drug is not approved in the West, the trial was single-country, and survival benefit has not been shown. If confirmed in the global HARMONi-3 and HARMONi-7 trials, PD-1 x VEGF bispecifics could replace PD-1 antibodies as the immunotherapy backbone.

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

2
Cutaneous squamous cell carcinomaNon-small-cell lung cancer

fronts

1
Immunotherapy

drugs

1
Under reviewBispecific antibody (PD-1×VEGF)
Ivonescimab

key papers

1
HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer